- Geron (NASDAQ:GERN) +20.4% AH on news that the New England Journal of Medicine would publish two papers showing positive results for GERN's flagship drug imetelstat, an inhibitor of the telomerase cancer cell enzyme.
- In two mid-stage clinical trials, GERN said the use of imetelstat suggested it works against malignant cells that cause essential thrombocythemia, a disease in which the body produces too many blood platelets, and against myelofibrosis, a bone marrow disease that disrupts the body's production of blood cells.